Bicycle Therapeutics Plc Forecast, price target & analysts
Bicycle Therapeutics Plc Target price 2026 - Analyst rating & recommendation
Bicycle Therapeutics Plc Classifications & Recommendation
Bicycle Therapeutics Plc Price Target
| Target Price | $11.22 |
| Price | $3.71 |
| Potential |
202.43%
register free of charge
|
| Number of Estimates | 9 |
|
9 Analysts have issued a price target Bicycle Therapeutics Plc 2027 .
The average Bicycle Therapeutics Plc target price is $11.22.
This is
202.43%
register free of charge
$14.70
296.23%
register free of charge
$5.05
36.12%
register free of charge
|
|
| A rating was issued by 16 analysts: 12 Analysts recommend Bicycle Therapeutics Plc to buy, 4 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Bicycle Therapeutics Plc stock has an average upside potential 2027 of
202.43%
register free of charge
|
Sales and Margin forecast 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Million $ | 72.59 | 15.65 |
| 105.75% | 78.44% | |
| EBITDA Margin | -332.41% | -1,034.20% |
| 41.94% | 211.12% | |
| Net Margin | -301.64% | -1,115.02% |
| 37.04% | 269.65% |
13 Analysts have issued a sales forecast Bicycle Therapeutics Plc 2026 . The average Bicycle Therapeutics Plc sales estimate is
This results in the following potential growth metrics:
5 Analysts have issued an Bicycle Therapeutics Plc EBITDA forecast 2026. The average Bicycle Therapeutics Plc EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
12 Bicycle Therapeutics Plc Analysts have issued a net profit forecast 2026. The average Bicycle Therapeutics Plc net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -3.16 | -2.50 |
| 8.97% | 20.89% | |
| P/E | negative | |
| EV/Sales | negative |
12 Analysts have issued a Bicycle Therapeutics Plc forecast for earnings per share. The average Bicycle Therapeutics Plc EPS is
This results in the following potential growth metrics and future valuations:
Bicycle Therapeutics Plc...
Current Bicycle Therapeutics Plc Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Needham |
Locked
➜
Locked
|
Locked | Jul 30 2026 |
| Morgan Stanley |
Locked
➜
Locked
|
Locked | Apr 08 2026 |
| Oppenheimer |
Locked
➜
Locked
|
Locked | Mar 18 2026 |
| Needham |
Locked
➜
Locked
|
Locked | Mar 18 2026 |
| Citizens |
Locked
➜
Locked
|
Locked | Mar 18 2026 |
| RBC Capital |
Locked
➜
Locked
|
Locked | Mar 18 2026 |
| Truist Securities |
Locked
➜
Locked
|
Locked | Nov 24 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
Needham:
Locked
➜
Locked
|
Jul 30 2026 |
|
Locked
Morgan Stanley:
Locked
➜
Locked
|
Apr 08 2026 |
|
Locked
Oppenheimer:
Locked
➜
Locked
|
Mar 18 2026 |
|
Locked
Needham:
Locked
➜
Locked
|
Mar 18 2026 |
|
Locked
Citizens:
Locked
➜
Locked
|
Mar 18 2026 |
|
Locked
RBC Capital:
Locked
➜
Locked
|
Mar 18 2026 |
|
Locked
Truist Securities:
Locked
➜
Locked
|
Nov 24 2025 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
